Maravai LifeSciences/MRVI

$7.72

4.74%
-
1D1W1MYTD1YMAX

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enable the development of drug therapies, diagnostics and vaccines and to support research on human diseases. Its companies provide products and services in the fields of nucleic acid synthesis and biologics safety testing to various biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. The Company operates through two segments. Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acid products to support the needs of customer research, therapeutic and vaccine programs. The segment also provides research products for labeling and detecting proteins in cells and tissue samples. Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities.

Ticker

MRVI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Carl Hull

Employees

650

Headquarters

San diego, United States

MRVI Metrics

BasicAdvanced
$1.84B
Market cap
-
P/E ratio
-$0.90
EPS
0.10
Beta
-
Dividend rate
$1.84B
0.10008
$16.62
$4.52
2.77M
8.002
7.414
132.118
133.575
-0.36%
-7.34%
-24.75%
-9.75%
6.351
4.402
30.249
-67.28%
-136.13%
0.57%

What the Analysts think about MRVI

Analyst Ratings

Majority rating from 13 analysts.
Buy

Price Targets

Average projection from 11 analysts.
27.98% upside
High $15.00
Low $6.50
$7.72
Current price
$9.88
Average price target

MRVI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-142.91% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$74.1M
10.93%
Net income
$-105.9M
1,554.69%
Profit margin
-142.91%
1,391.75%

MRVI Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 184.62%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.03
-
-$0.01
$0.01
-
Expected
$0.04
$0.01
$0.01
-$0.01
-$0.03
Surprise
-17.24%
-
-257.13%
-184.62%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Maravai LifeSciences stock?

Maravai LifeSciences (MRVI) has a market cap of $1.84B as of April 23, 2024.

What is the P/E ratio for Maravai LifeSciences stock?

The price to earnings (P/E) ratio for Maravai LifeSciences (MRVI) stock is 0 as of April 23, 2024.

Does Maravai LifeSciences stock pay dividends?

No, Maravai LifeSciences (MRVI) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next Maravai LifeSciences dividend payment date?

Maravai LifeSciences (MRVI) stock does not pay dividends to its shareholders.

What is the beta indicator for Maravai LifeSciences?

Maravai LifeSciences (MRVI) has a beta rating of 0.1. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Maravai LifeSciences stock price target?

The target price for Maravai LifeSciences (MRVI) stock is $9.88, which is 27.98% above the current price of $7.72. This is an average based on projections from 11 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Maravai LifeSciences stock

Buy or sell Maravai LifeSciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing